Commercial Launch Follows Successful Beta Testing of Prevencio’s Highly Accurate AI-driven HART Tests
Prevencio, Inc. today announces an Agreement with Atlas Genomics to commercially launch its highly accurate, AI-driven HART blood tests for heart disease and risk of heart attack, stroke, and cardiovascular death. The HART blood tests are now available and can be ordered through your physician.
Atlas Genomics is a CLIA-certified, high complexity diagnostic lab providing the highest quality of testing, service, and technology. Prevencio’s and Atlas’ partnership incorporates the use of Microsoft’s Azure AI-computing cloud for HART algorithm processing, scoring, report generation and secure physician delivery of Prevencio’s HART test reports. Additional terms of the deal are not disclosed.
Technology and commercial laboratory companies have been in heated pursuit of integrating technology, including AI and machine learning, with healthcare data. Last year, Prevencio announced a partnership with Microsoft for AI-cloud computing services as well assistance in scaling commercialization.
“We are excited to partner with Atlas Genomics to commercially launch our HART tests for patient use on Microsoft’s secure cloud,” stated Rhonda Rhyne, Prevencio’s Chief Executive Officer. “Based on preliminary physician and patient feedback, we feel there is a definite need for our HART tests. They provide highly accurate results in an easy-to-understand report, allowing physicians and patients to monitor and detect changes in cardiac health conditions.”
Prevencio’s AI-driven HART tests were developed in partnership with Massachusetts General Hospital and have consistently demonstrated higher accuracy as compared to standard risk scores or standard-of-care tests.
Dr. Michael Kalnoski, Atlas Genomics’ CEO and Chief Medical Officer, added, “We are pleased to partner with Prevencio to provide actionable data to battle heart disease, the number one cause of death in our nation. With more than 15 million US heart disease patients, and tens of millions of additional patients at risk, there is a clear unmet need for highly accurate, AI-based, multi-protein blood tests.”
